Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org
-- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Monday, September 19, 2016
Registry Data: Lemtrada More Effective than Competing MS Tx
Click here to receive MS news via e-mail
September 17, 2016
LONDON -- Data from a large multiple sclerosis patient registry suggest that alemtuzumab (Lemtrada) is more effective in key efficacy measures than two other common drugs for MS and similar in efficacy to a third, a researcher said here
In an analysis covering some 4,500 patients who had recently started alemtuzumab, fingolimod (Gilenya), interferon-beta-1a (Rebif, Avonex), or natalizumab (Tysabri), alemtuzumab was better than fingolimod and interferon for at least one of the following outcome measures: relapse risk, disability progression, or functional improvement, and was not less effective on any efficacy measure, reported Tomas Kalincik, MD, PhD, of the University of Melbourne in Australia.
Alemtuzumab and natalizumab were in a virtual dead heat for relapse prevention and reducing disability progression, Kalincik told attendees at an oral late-breaker session during the European Committee for Treatment and Research in Multiple Sclerosis annual meeting.
There was only one outcome analyzed in the entire study for which alemtuzumab was inferior to another drug: natalizumab was more likely to produce an improvement in functional ability during the first year of treatment, though not in subsequent years.
MS Views and News
Providing educational information, resources and services for those affected by MS